PURPOSE: The objective of this study is to develop a population pharmacokinetic (PK) model that describes the subcutaneous (SC) depot formation of gonadotropin-releasing hormone (GnRH) antagonist degarelix, which is being developed for treatment of prostate cancer, exhibiting dose-volume and dose-concentration dependent absorption. METHODS: The PK analysis is made in NONMEM through joint analysis of data from two phase I clinical studies; an intravenous infusion study and a single SC dose escalation study. The SC absorption is modeled using an approximation to Ficks' second law of diffusion out of a spherical depot. The dose-volume effect on the SC release is estimated using a B-spline basis whereas the bioavailability is modeled as a function of the dose-concentration. RESULTS: The SC depot model is approximated by using two concentric spherical compartments for the SC absorption combined with a two-compartment disposition model. The results indicate that the volume effect is most apparent at low injection volumes whereas the effect is diminishing at higher injection volumes. The dose-concentration effect on the bioavailability is estimated to decrease at increasing dose-concentrations. CONCLUSIONS: The presented SC depot model describes the PK profile of GnRH antagonist degarelix. This modeling approach might also be applicable for other depot-formulated drugs exhibiting complex PK profiles.
PURPOSE: The objective of this study is to develop a population pharmacokinetic (PK) model that describes the subcutaneous (SC) depot formation of gonadotropin-releasing hormone (GnRH) antagonist degarelix, which is being developed for treatment of prostate cancer, exhibiting dose-volume and dose-concentration dependent absorption. METHODS: The PK analysis is made in NONMEM through joint analysis of data from two phase I clinical studies; an intravenous infusion study and a single SC dose escalation study. The SC absorption is modeled using an approximation to Ficks' second law of diffusion out of a spherical depot. The dose-volume effect on the SC release is estimated using a B-spline basis whereas the bioavailability is modeled as a function of the dose-concentration. RESULTS: The SC depot model is approximated by using two concentric spherical compartments for the SC absorption combined with a two-compartment disposition model. The results indicate that the volume effect is most apparent at low injection volumes whereas the effect is diminishing at higher injection volumes. The dose-concentration effect on the bioavailability is estimated to decrease at increasing dose-concentrations. CONCLUSIONS: The presented SC depot model describes the PK profile of GnRH antagonist degarelix. This modeling approach might also be applicable for other depot-formulated drugs exhibiting complex PK profiles.
Authors: G de Pinieux; M E Legrier; F Poirson-Bichat; Y Courty; R Bras-Gonçalves; A M Dutrillaux; F Némati; S Oudard; R Lidereau; P Broqua; J L Junien; B Dutrillaux; M F Poupon Journal: Am J Pathol Date: 2001-08 Impact factor: 4.307
Authors: Christoffer W Tornøe; Henrik Agersø; Henrik A Nielsen; Henrik Madsen; E Niclas Jonsson Journal: J Pharmacokinet Pharmacodyn Date: 2004-12 Impact factor: 2.745
Authors: Christoffer W Tornøe; Henrik Agersø; Thomas Senderovitz; Henrik A Nielsen; Henrik Madsen; Mats O Karlsson; E Niclas Jonsson Journal: Br J Clin Pharmacol Date: 2006-11-10 Impact factor: 4.335
Authors: Christoffer W Tornøe; Rune V Overgaard; Henrik Agersø; Henrik A Nielsen; Henrik Madsen; E Niclas Jonsson Journal: Pharm Res Date: 2005-08-03 Impact factor: 4.200
Authors: Yassine Kamal Lyauk; Daniël M Jonker; Trine Meldgaard Lund; Andrew C Hooker; Mats O Karlsson Journal: AAPS J Date: 2020-08-27 Impact factor: 4.009